about
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisHow the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesMapping the laminin receptor binding domains of Neisseria meningitidis PorA and Haemophilus influenzae OmpP2.An epidemiological review of changes in meningococcal biology during the last 100 yearsPhenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010.Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens.Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvantProspects for eradication of meningococcal diseaseNew versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.Genome-based bacterial vaccines: current state and future outlook.The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative.Neisseria meningitidis B vaccines: recent advances and possible immunization policies.In silico analysis and modeling of ACP-MIP-PilQ chimeric antigen from Neisseria meningitidis serogroup BThe multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.Challenges and opportunities for Meningococcal vaccination in the developing world.
P2860
Q26779489-BA8299B4-5A40-46AE-8DCB-F4DA8DA5A527Q26782340-BE2C0CFF-CADC-458C-8361-7AA0A805792AQ31104611-E0A82EF8-FEEC-49FD-AE53-41B1315EAB1BQ33850814-256A6A81-53FB-49F7-90A1-31F5F8AAC91AQ34618580-43CF3B83-A7A1-4450-AAE0-D5FF60C2E766Q34776133-D5204287-149D-4CBB-BC34-A3718F2F84BAQ35108361-3C4F9F09-24AD-4024-832D-64F3D6CAB58BQ35887397-BA73E572-24CB-4240-A289-12997FA25017Q36440358-00935AA6-E4FF-4C7C-A8C9-4BD82BBAFE69Q37690815-A3AAD4CC-1CAC-4765-9218-F84DAF2741DAQ38099207-6F0CE150-F07D-4DE7-A481-2D848295F321Q38126097-5F0217A7-D91C-4FCC-B526-CF29835887DDQ38183156-43FBB87D-8A6D-41CE-9820-821A93C75D76Q38534123-3D3D3110-BFD6-4031-A0FB-4DF2C2DC6DBCQ38599522-3809F981-F7FE-4856-ABA2-A592752733A3Q49377063-8F9DED9A-C00C-4EA1-83E9-5EA882580EA2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neisseria meningitidis B vaccines.
@en
Neisseria meningitidis B vaccines.
@nl
type
label
Neisseria meningitidis B vaccines.
@en
Neisseria meningitidis B vaccines.
@nl
prefLabel
Neisseria meningitidis B vaccines.
@en
Neisseria meningitidis B vaccines.
@nl
P2860
P50
P356
P1476
Neisseria meningitidis B vaccines
@en
P2093
Daniela Amicizia
P2860
P304
P356
10.1586/ERV.11.103
P577
2011-09-01T00:00:00Z